October 24, 2012
Kaken Pharmaceutical on October 23 filed a new drug application (NDA) for efinaconazole (development code: KP-103), a treatment for onychomycosis, the company said on the same day. If approved, efinaconazole would be the first topical drug for onychomycosis in Japan,...read more